Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Debt Repayment

Cash used to repay borrowings during the period.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment declines year over year

Q1 FY2026 debt repayment of $74.99M fell 25.0% year over year, in line with the -25.0% change in trailing-twelve-month debt repayment.

Context

  • Debt repayment amounted to 7680.0% of revenue in FY2025, up 7680.0 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -25.0% holds above the trailing-twelve-month pace of -25.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$74.99M— QoQ
Last fiscal yearDec 2025
$99.84M— YoY
LTMMar 2026
$74.99M-25.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
99.84M USD
Year-over-year change
—

Debt Repayment vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.0% is the 3rd highest of 5, against a peer median of -23.4%.
  • Debt repayment amounts to 5768.6% of revenue for INBX, versus a peer median of 4.0%.
INBX Competitors
Debt Repayment for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INBXInhibrx Biosciences, Inc.LTM Mar 2026$74.99M USD-25.0%—5768.6%
GENBGenerate Biomedicines, Inc.FY2025$8.16M USD-26.6%—25.6%
ABSIAbsci CorporationLTM Mar 2026$2.85M USD-20.2%—155.1%
IMTXImmatics N.V.LTM Mar 2026€1.47M EUR-55.0%—4.0%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$476K USD+0.2%+7.6%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$0 USD——0.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding INBX) —-23.4%+7.6%4.0%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(81.77M)(145.23M)(239.73M)1.69B(140.06M)
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
Deferred Income Tax(9K)0000
Stock-Based Compensation15.05M20.45M24.85M58.52M11.14M
Change in Working Capital(17.52M)3.16M15.35M52.05M(7.61M)
Accounts Receivables(167K)130K(521K)381K243K
Inventory(11.03M)0000
Accounts Payables(4.64M)(705K)2.11M17.9M(3.3M)
Other Working Capital(1.67M)3.74M13.76M33.77M(4.56M)
Other Non-Cash Items2.73M5.09M5.03M(1.99B)4.25M
Operating Cash Flow(80.32M)(115.3M)(193.31M)(194.41M)(129.79M)
Capital Expenditures(864K)(686K)(4.59M)(2.6M)(31K)
Acquisitions (Net)55K0003K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(809K)(686K)(4.59M)(2.6M)(28K)
Debt Repayment000099.84M
Common Stock Issued40.2M129.74M201.96M71.68M1.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities83.77M128.81M000
Financing Cash Flow83.77M258.55M201.96M71.68M101.45M
Effect of Forex Changes00000
Net Change in Cash2.64M142.56M4.06M(125.33M)(28.38M)
Free Cash Flow(81.19M)(115.99M)(197.9M)(197.01M)(129.83M)

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.